Imugene Ltd
IMU
Company Profile
Business description
Imugene Ltd specializes in a clinical-stage immuno-oncology company. Its products include HER-Vaxx, PD1-Vaxx, CF33 and CF33 CD19. HER-Vaxx is a proprietary HER2 +ve cancer vaccine that stimulates a polyclonal antibody response to HER2/neu. The company is also developing B-cell peptide cancer vaccines and therapeutics. Its only operating segment is the Research and Development of oncolytic immunotherapies.
Contact
4-6 Bligh Street
Suite 12.01, Level 12
SydneyNSW2000
AUSSector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
30 June 2025
Employees
5
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,091.20 | 38.00 | 0.47% |
| CAC 40 | 7,790.71 | 125.37 | -1.58% |
| DAX 40 | 22,163.49 | 298.03 | -1.33% |
| Dow JONES (US) | 42,001.76 | 417.86 | 1.00% |
| FTSE 100 | 8,582.81 | 76.04 | -0.88% |
| HKSE | 23,283.80 | 164.22 | 0.71% |
| NASDAQ | 17,299.29 | 23.70 | -0.14% |
| Nikkei 225 | 35,825.59 | 208.03 | 0.58% |
| NZX 50 Index | 12,208.81 | 61.19 | -0.50% |
| S&P 500 | 5,611.85 | 30.91 | 0.55% |
| S&P/ASX 200 | 7,888.00 | 44.60 | 0.57% |
| SSE Composite Index | 3,351.10 | 15.35 | 0.46% |